One year after leaving GSK, Emmanuel Hanon jumps to Medicxi-backed vaccine startup with an eye on RSV
After 20 years of service at GSK — leading global vaccines R&D for the last seven — Emmanuel Hanon left last year for a wellness company with a gut microbiome focus called Viome.
One of the major reasons for the departure, according to him, was in essence to learn something new and to be exposed to a new environment.
But it didn’t take long for him to return to the vaccine world full-time. Hanon has now taken the top position at a Medicxi-backed biotech working on a vaccine for RSV called Vicebio.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.